Baohe Pingwei power plus neoadjuvant chemotherapy for gastric cancer

Table 3 Comparison of clinical data of patients with different curative effects

Characteristic		Total number of cases (n = 80)	Effective (n = 62)	Invalid (n = 18)	χ2/t	P value
Use Baohe Pingwei powder		26 (32.50)	24 (38.71)	2 (11.11)	4.843	0.029
Age (mean ± SD, years)		68.51 ± 1.94	68.67 ± 2.13	68.02 ± 2.04	1.150	0.254
Gender	Male	63 (78.75)	50 (80.65)	13 (72.22)	0.195	0.659
	Female	17 (21.25)	12 (19.35)	5 (27.78)
Tumor location	Gastric antrum or pylorus	57 (71.25)	45 (72.58)	12 (66.67)	0.456	0.648
	Stomach body	11 (13.75)	8 (12.90)	3 (16.67)
	Gastric fundus or cardia	12 (15.00)	9 (14.52)	3 (16.67)
Clinical staging	Phase II	39 (48.75)	31 (50.00)	8 (44.44)	0.172	0.678
	Phase III	41 (51.25)	31 (50.00)	10 (55.56)
Surgical scope	Partial excision	42 (52.50)	33 (53.23)	9 (50.00)	0.058	0.809
	Fully cut	38 (47.50)	29 (46.77)	9 (50.00)
Tumor size	< 2 cm	15 (18.75)	13 (20.97)	2 (11.11)	2.172	0.030
	2-5 cm	50 (62.50)	41 (66.13)	9 (50.00)
	> 5 cm	15 (18.75)	8 (12.90)	7 (38.89)
Degree of differentiation	High	4 (5.00)	2 (3.23)	2 (11.11)	2.675	0.008
	In	24 (30.00)	15 (24.19)	9 (50.00)
	Low	52 (65.00)	45 (72.58)	7 (38.89)
Smoke	Have	33 (41.25)	27 (43.55)	6 (33.33)	0.601	0.438
	Without	47 (58.75)	35 (56.45)	12 (66.67)
Drink	Have	55 (68.75)	44 (70.97)	11 (61.11)	0.601	0.427
	Without	25 (31.25)	18 (29.03)	7 (38.89)
Hypertension	Have	36 (45.00)	26 (41.94)	10 (55.56)	1.667	0.197
	Without	44 (55.00)	37 (59.68)	7 (38.89)
Diabetes mellitus	Have	30 (37.50)	24 (38.71)	6 (33.33)	0.172	0.678
	Without	50 (62.50)	38 (61.29)	12 (66.67)
CD3+ (mean ± SD, %)	Before treatment	56.59 ± 1.67	57.36 ± 2.34	56.84 ± 2.01	0.0855	0.395
	After treatment	37.34 ± 1.58	45.67 ± 2.03	32.16 ± 1.35	26.521	0.000
CD4+ (mean ± SD, %)	Before treatment	39.46 ± 1.26	39.15 ± 2.06	40.12 ± 2.37	1.700	0.082
	After treatment	25.64 ± 1.03	30.58 ± 1.64	21.34 ± 1.42	21.642	0.000
CA19-9 (mean ± SD, %)	Before treatment	71.69 ± 2.45	71.64 ± 2.43	72.87 ± 2.16	1.935	0.057
	After treatment	36.98 ± 2.06	35.69 ± 1.26	38.59 ± 2.16	7.207	0.000
CA242 (U/mL)	Before treatment	44.27 ± 0.28	44.17 ± 0.25	44.15 ± 0.03	0.337	0.737
	After treatment	26.31 ± 1.34	37.12 ± 2.13	12.24 ± 0.15	49.299	0.000
IL-6 (mean ± SD, ng/mL)	Before treatment	428.94 ± 2.69	429.67 ± 2.16	429.32 ± 2.15	0.606	0.546
	After treatment	317.65 ± 2.36	310.84 ± 2.67	328.12 ± 2.37	24.751	0.000
IL-10 (mean ± SD, ng/mL)	Before treatment	92.84± 1.52	92.98 ± 1.76	92.48 ± 1.38	1.109	0.271
	After treatment	234.18 ± 2.68	61.08 ± 1.26	86.41 ± 1.28	74.824	0.000
TNF-α (mean ± SD, ng/mL)	Before treatment	321.23 ± 2.03	321.08 ± 0.99	321.54 ± 2.31	1.237	0.220
	After treatment	261.33 ± 2.07	220.09 ± 1.28	319.26 ± 2.17	243.829	0.000

Data are presented as n (%) unless otherwise noted. SD: Standard deviation.